Avantor to buy Masterflex in $2.9bn deal
Avantor Inc
$21.07
10:59 31/12/24
US laboratory products provider Avantor has agreed to buy the Masterflex bioprocessing business from privately-held Antylia Scientific for $2.9bn in cash.
Masterflex AG
€9.38
17:30 30/12/24
Illinois-based Masterflex is a global manufacturer of peristaltic pumps and aseptic single-use fluid transfer technologies with estimated 2022 revenues of $300m.
Avantor said the deal strengthens its offering across all bioproduction platforms including monoclonal antibodies (mAbs), cell and gene therapy and mRNA. It also supports both therapy and vaccine manufacturing, including Covid-19.
President and chief executive Michael Stubblefield said: "The acquisition of Masterflex reflects our commitment to the biopharma industry, and our ability to identify and execute on value-creation opportunities.
"The business enhances our portfolio of proprietary technologies and strengthens our position in the highest growth segments of the market. Both Avantor and Masterflex share a strong culture of innovation and excellence, and we look forward to welcoming Masterflex's highly skilled team to the Avantor family."